News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Cenovus Energy (TSE:CVE) shares recently crossed above their 200-day moving average, signaling improved technical momentum. The company reported strong quarterly earnings and increased its dividend, yet insiders have sold a significant number of shares. Analysts maintain a bullish outlook with an average "Buy" rating …
Sharemaestro market context Trend signal active 52 weeks +94.5%Dimensional Fund Advisors LP increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 9.2% in the first quarter, purchasing an additional 225,588 shares, bringing its total holdings to 2.67 million shares valued at approximately $19.8 million. This acquisition reflects a broader institutional interest in NeoGenomics, …
Sei Investments Co. significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 320.7% during the first quarter, now holding 466,199 shares valued at $3.46 million. This move is mirrored by other institutional investors, collectively owning 98.5% of the company's stock, despite a recent insider …
Xenon Pharmaceuticals' azetukalner NDA filing remains on track following a productive pre-NDA meeting with the FDA, according to RBC. However, the full article content is only available to premium subscribers.
NeoGenomics (NEO) reported a return to profitability in Q2 2026 with US$2.24 million net income and raised its full-year 2026 revenue outlook to US$802 million–US$806 million, indicating improving operational performance. This positive shift strengthens the company's investment narrative, emphasizing its role as a specialized …
NeoGenomics, Inc. (BX:NG9) generated 576.61 million CHF in revenue last year. The "Client Direct Billing" segment was the top performer, contributing 411.32 million CHF, a decrease from the previous year. The United States was the primary regional contributor, accounting for all of the company's …
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 earnings call highlighted significant progress in advancing azetukalner, with a successful pre-NDA meeting for focal seizures and a strong cash position of $1.2 billion, funding operations into 2029. The company also detailed its broad pipeline, including five additional …
Enovis Corporation reported strong second-quarter 2026 results, showing 5% organic growth, significant margin expansion, and improved free cash flow. Despite beating earnings expectations and reaffirming full-year guidance, the stock declined 8.4%, reflecting investor concerns about near-term headwinds and the absence of raised guidance. The …
FMR LLC reported a 5.7% beneficial ownership stake in Amphenol Corporation's Class A common stock, totaling 70,486,300.18 shares as of June 30, 2026, via an Amendment No. 27 to a Schedule 13G filing. Abigail P. Johnson is also reported with the same beneficial ownership, …
Earnings Call Insights: Enovis (ENOV) Q2 2026 MANAGEMENT VIEW * CEO Damien McDonald said Q2 results showed “the strength and stability of our diversified product portfolio” and reported “organic growth of 5%, driven by 6% organic growth in Recon and 3% organic growth in …
Earnings Call Insights: 10x Genomics (TXG) Q2 2026 MANAGEMENT VIEW * "Revenue for the second quarter was $151 million" (CEO Serge Saxonov) and management highlighted a nonrecurring item: "we recognized $1.6 million of license and royalty revenue in connection with our settlement with Takara" …
Cenovus Energy recently reported strong second-quarter 2026 results, showing higher sales, net income, and upstream production, alongside updated guidance and capital returns through dividends and share buybacks. Despite a significant year-to-date share price increase of 64.70% and a five-year return of 326.13%, the company …
Enovis is reaffirming its financial guidance for 2026. The company anticipates achieving $2.5 billion in revenue and an adjusted EBITDA margin of 23% by that year. This reiteration suggests confidence in their ongoing business strategies and growth trajectory.
Xenon Pharmaceuticals Inc. announced its Q2 2026 financial results, highlighted by the continued progress of its lead drug azetukalner, with an NDA submission for FOS on track for Q3 2026 and Phase 3 data for MDD expected in H1 2027. The company reported $1.2 …
10x Genomics reported a Q2 2026 total revenue of $151.0M, a 13% decrease from Q2 2025, primarily due to the absence of large, non-recurring patent-license settlements from the previous year. Despite this, underlying products and services revenue grew by 3% to $149.1M, driven by …
Terreno Realty Corporation (TRNO) is an acquirer, owner, and operator of industrial real estate in six major coastal U.S. markets. The company recently executed new renewal leases totaling 233,000 square feet at Countyline Corporate Park Phase III in Hialeah, Florida. Terreno's stock closed at …
RenovoRx Inc. announced that its RenovoCath drug-delivery device was used commercially for the first time to treat a sarcoma patient at CARTI Cancer Center. This marks an expansion beyond the company's prior focus on pancreatic cancer, demonstrating the device's potential for local chemotherapy delivery …
Enovis Corporation's shares fell 12.8% after reporting second-quarter earnings, despite revenue and adjusted earnings surpassing Wall Street expectations. The decline was attributed to a weaker full-year earnings per share outlook and a significant contraction in the company's adjusted operating margin, which fell 6.7 percentage …
Xenon Pharmaceuticals is set to release its second-quarter earnings, with investors keenly watching its cash position and regulatory timeline as it approaches an FDA submission for its drug, azetukalner. Analysts anticipate a loss of $1.14 per share on $1.5 million in revenue. The company …
This article provides detailed cash flow statements for Kenon Holdings Ltd (76N.DU), covering annual and quarterly data up to December 31, 2025. It includes figures for operating, investing, and financing cash flows, capital expenditure, debt issuance and repayment, stock repurchase, and free cash flow. …
Search by ticker symbol or company name and select a result to open its chart.